XML 79 R56.htm IDEA: XBRL DOCUMENT v3.22.4
Collaboration and License Agreements- Jazz Pharmaceuticals (Details)
$ in Thousands
1 Months Ended 12 Months Ended
Aug. 31, 2017
USD ($)
item
Option
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Nov. 30, 2022
USD ($)
Collaborative Agreements disclosures          
Revenue from contract with customer   $ 108,782 $ 69,856 $ 132,299  
Potential milestone payment         $ 125,000
Contract with customer liability   50,211 92,068 110,109  
Revenue recognized, previously deferred   49,462 22,765 61,872  
Jazz          
Collaborative Agreements disclosures          
Number of early stage ADC programs | item 2        
Potential milestone payment $ 100,000        
Term of agreement 7 years        
Offset to research and development expense     6,700 6,700  
Revenue recognized, previously deferred       60,500  
Upfront payment | Jazz          
Collaborative Agreements disclosures          
Revenue from contract with customer $ 75,000        
Upfront arrangement consideration number of license options | Option 3        
License and milestone fees          
Collaborative Agreements disclosures          
Revenue from contract with customer   76,027 22,650 63,742  
Revenue recognized, previously deferred   2,900      
Research and development support          
Collaborative Agreements disclosures          
Revenue from contract with customer   $ 940 $ 398 $ 28